logo
Singapore Advances Patented Signal Embedded Power Solution to Close the 200-Year Divide Between Electricity and Telecoms

Singapore Advances Patented Signal Embedded Power Solution to Close the 200-Year Divide Between Electricity and Telecoms

Signal Embedded Power Line (SEPL) embeds real-time control signals within existing power lines
'I am grateful to Prime Minister Lawrence Wong for the opportunity to serve. It is heartening to see the PAP leadership demonstrating openness to new ideas that can strengthen Singapore's future.'— Kannappan Chettiar
SINGAPORE, April 29, 2025 / EINPresswire.com / -- Since the early 19th century, electricity and communication have evolved along separate technological paths. While the telegraph introduced the transmission of binary information through wires, energy systems like Volta's battery and Edison's electric grid focused solely on delivering power. These domains remained isolated — power systems could not communicate, and communication systems could not energize.
Today, this historical separation is finally being overcome.
A groundbreaking innovation called the Signal Embedded Power Line (SEPL) has been formally presented to Singapore's Energy Market Authority (EMA) and national leadership, offering a transformational pathway for energy conservation and infrastructure intelligence.
SEPL enables power delivery and real-time communication to coexist silently over the same conductor — without software, cloud systems, IoT devices, or vulnerable network architectures.
Developed by Singapore inventor Kannappan Chettiar through globally patented Para-Series Field Embedding technology, the Signal Embedded Power Line (SEPL) resolves the century-old divide that kept energy and communication systems isolated due to electrical noise interference.
Kannappan, Founder of Switching Battery® Inc., also pioneered the Switching Battery® Dynamic Para-Series Connections — innovations now recognized with patents granted across the United States, Europe, India, China, and other leading jurisdictions.
SEPL represents a world-first breakthrough:
A system that allows power delivery and real-time communication to coexist silently over the same conductor — without software, cloud systems, IoT devices, or cybersecurity vulnerabilities.
🌊 How SEPL Works: The Para-Series Magic
SEPL operates on a breakthrough para-series architecture:
• In Parallel Mode (minimum ~4V): Analog signals are embedded deep within the flow, silently and without disruption. This simultaneously enables real-time control, cell balancing, and communication pulses.
• In Series Mode (e.g., 12V or 20V for LED streetlights): Power is delivered efficiently to loads like lighting systems and appliances.
• Micro-Switching Magic: The system intermittently shifts — for just milliseconds — between series and parallel states, embedding signals during normal power delivery without visible interruption. This allows embedded intelligence without needing internet, cloud commands, or additional wiring.
🔥 Why It Matters:
• Energy Conservation and Dynamic Control: SEPL allows streetlights to be turned on/off, dimmed, or adapted to weather conditions. Future possibilities include 'dancing streetlights' for pedestrian guidance, or emergency warnings without new infrastructure.
• True Infrastructure Integration: Unlike Internet-based IoT controls, which require costly, unreliable, and complex networks, SEPL rides silently inside existing power lines — no internet towers, no firmware updates, no maintenance burden.
• Historic Electrical Barrier Broken: Traditionally, power lines and telecommunications could not be merged due to electrical noise disrupting signal quality.
SEPL overcomes this century-old limitation using the ocean metaphor:
• At the surface, waves and tsunamis create noise — but deep below, the ocean remains still and calm.
SEPL hides its signals deep within the energy flow, where noise cannot interfere. This miracle-like breakthrough transforms how cities, grids, and even remote villages can communicate with their energy systems — cheaply, reliably, and beautifully.
🌍 Singapore: The First to Lead?
The potential impact for Singapore alone is extraordinary:
• Annual savings exceeding S$1.6 billion through immediate energy conservation.
• Deployment cost estimated at S$84 million, achieving payback within three months.
• Retrofittable to existing infrastructure, offering rapid national deployment without disruption.
Following an official request for technical specifications by EMA, a formal briefing offer has been extended. Public documentation of the proposal and technical overview has been made available to ensure transparency and public trust.
In response to the government's request for technical specifications, Kannappan said, 'I am grateful to Prime Minister Lawrence Wong for the opportunity to serve. It is heartening to see the PAP leadership demonstrating openness to new ideas that can strengthen Singapore's future.'
About Kannappan Chettiar
Kannappan Chettiar is the Founder of Switching Battery® Inc., inventor of multiple energy system patents, and author of Switching Battery Dynamic Para-Series Connections. His life's work bridges technology, natural law, and universal flow to create resilient, sustainable energy systems for the 21st century and beyond.
'Someday, every battery will be a Switching Battery® — and every current will carry both power and wisdom.'
Kannappan Chettiar
SWITCHING BATTERY INC
+1 831-643-5919
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao
JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao

Yahoo

timean hour ago

  • Yahoo

JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao

SHANGHAI, June 4, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that its new drugapplication (NDA) for the CAR-T cell immunotherapy product Carteyva® (relma-cel, targeting CD19) was approved by the Macao Special Administrative Region Government's Drug Regulatory Authority. This marks the first overseas market access for the product after its approval in mainland China, as well as a significant breakthrough in JW Therapeutics' global strategy. The approval covers three major indications, including: Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy; Adult patients with refractory or relapsed within 24 months follicular lymphoma after two or more lines of systemic therapy; Adult patients with relapsed or refractory mantle cell lymphoma after second line or above systemic treatment, including treatment with Bruton tyrosine kinase JW Therapeutics' first commercial product, the marketing approval of Carteyva® in Macao will further expand its accessibility in hematological oncology. Mr. Min LiuChairman and CEO of JW Therapeutics"The approval of Carteyva® in Macao marks the official launch of JW Therapeutics' internationalization journey, demonstrating our technical strength and regulatory recognition in the field of cell therapy. As our first overseas market, Macao lays a solid foundation for our expansion into Asia-Pacific and global markets. In the future, we'll speed up regional commercialization and strengthen global R&D and manufacturing collaboration to offer hope to more patients." View original content: SOURCE JW Therapeutics Sign in to access your portfolio

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

Yahoo

timean hour ago

  • Yahoo

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

HENDERSON, Nevada, June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems. Dr Sato, a key opinion leader is Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center, one of the largest referral hospitals in Japan. AMAMS 2025 is taking place in Thailand. Commenting on the results Dr Sato said: "The Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool, particularly for differentiating between benign and malignant conditions such as Canine Chronic Enteropathy and Gastrointestinal Lymphoma." Kiyotaka Fujiwara, Chief Operating Officer at Fujifilm Vet Systems, added: "We are delighted that leading veterinarian Dr Sato has adopted the Nu.Q® Vet Cancer Test in Japan, and not only researching, but publishing specific use cases. We believe this will further raise the awareness of the test and drive wider adoption." The presentations: Title: "Diagnostic Utility of Plasma Nucleosome Concentration in Differentiating Canine Chronic Enteropathy from Gastrointestinal Lymphoma" Presenter: Kentaro NabeshimaDate and Time: Thursday, June 5, 2025, 1:40PM – 1:50PM (ICT)Venue: Room 108Key Conclusion: Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool for distinguishing CE from GIL, with particularly high levels observed in medium-to-large cell "Evaluation of Plasma Nucleosome Concentrations as a Biomarker for Canine Nasal Tumors"Presenter: Chihoko TakahashiDate and Time: Thursday, June 5, 2025, 3:30PM – 3:40PM (ICT)Venue: Room 108 About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only. Media Enquiries:Louise Batchelor, Volition, mediarelations@ +44 (0)7557 774620 Investor Relations:Jeremy Feffer, LifeSci Advisors, jfeffer@ +1-212-915-2568 Safe Harbor Statement Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America. View original content: SOURCE VolitionRx Limited Sign in to access your portfolio

Gold Holds Gain as Soft US Data Bolster Bets on Fed Rate Cuts
Gold Holds Gain as Soft US Data Bolster Bets on Fed Rate Cuts

Yahoo

time2 hours ago

  • Yahoo

Gold Holds Gain as Soft US Data Bolster Bets on Fed Rate Cuts

(Bloomberg) -- Gold held gains, after weaker-than-expected US data reinforced expectations that the Federal Reserve will cut interest rates at least twice this year to prevent a recession. ICE Moves to DNA-Test Families Targeted for Deportation with New Contract The Global Struggle to Build Safer Cars At London's New Design Museum, Visitors Get Hands-On Access NYC Residents Want Safer Streets, Cheaper Housing, Survey Says The Buffalo Architect Fighting for Women in Design Bullion traded near $3,375 an ounce, following a 0.6% increase on Wednesday, after separate reports showed a contraction in US service providers and a deceleration in hiring. Treasury yields fell after the prints, with swap traders pricing in two Fed reductions in October and December. Lower rates are typically a tailwind for gold, which doesn't bear interest. Elsewhere, fears about worsening friction between the US and some of its major trading partners resurfaced after President Donald Trump doubled steel and aluminum tariffs to 50%. Separately, he labeled Chinese counterpart Xi Jinping as 'extremely hard to make a deal with'. Bullion is up almost 30% this year and hit a record high in April, as an expanding US-led tariff war bolstered its appeal as a haven. Central banks have also been a major driving force, with their buying spree expected to continue amid geopolitical tensions and concerns about overexposure to the dollar. Spot gold edged up 0.1% to $3,375.21 an ounce as of 7:41 a.m. in Singapore. The Bloomberg Dollar Spot Index was down 0.1%, following a 0.4% loss on Wednesday. Silver was flat, while platinum and palladium rose. Looking ahead, a US jobs report due Friday is expected to show that growth in nonfarm payrolls slowed and the unemployment rate remained steady. Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again YouTube Is Swallowing TV Whole, and It's Coming for the Sitcom Millions of Americans Are Obsessed With This Japanese Barbecue Sauce Is Elon Musk's Political Capital Spent? Trump Considers Deporting Migrants to Rwanda After the UK Decides Not To ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store